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have been demonstrated in humans and mice [1,2]. The genetic 
deficiency of FoxP3 (transcription factor involved in the induction 
of the regulatory functions of T lymphocytes) or IPEX syndrome 
(Immunodeficiency, Polyendocrinopathy and Enteropathy, 
X-Linked Syndrome) produces a severe autoimmunity and food 
allergy in patients. A similar clinical picture is observed in Foxp3-
null mice [3].
There is no treatment approved for food allergy and the currently 
accepted standard of care is allergen avoidance, accompanied 
by nutritional counseling [4]. Nevertheless, patients are prone 
to potential accidental exposure to the offending allergen with 
significant morbidity as well as mortality if anaphylaxis is produced 
in IgE-mediated allergic patients. This means that patients should be 
prepared for an eventual anaphylactic reaction with anti-histamines 
or injectable epinephrine. There is therefore much effort being made 
to develop disease-modifying therapies for IgE-mediated food allergy. 
In the context of treating allergic diseases, immunotherapy has 
been widely and empirically used during the last century. However, 
in the last years, results are by large showing that mucosal-based 
immunotherapy can mitigate the disease progress and it is nowadays 
the only disease-modifying treatment that could potentially cure 
allergy [5,6]. The step-wise administration of small amounts of the 
allergen through different mucosa, followed by maintenance dosing, 
induces specific tolerance mechanisms that restore the impaired 
immune-regulation observed in these patients [7,8]. In addition, 
the clinical therapeutic effect achieved with allergen-specific 
immunotherapy made restriction diet a currently controversial and 
debatable decision. Furthermore, there is emerging evidence showing 
that in high-risk patient with severe symptoms, prevention should 
contemplate the administration of the allergen even in patients with 
less than 1 year old [9]. In this prospective and randomized trial 
authors revealed that the early administration of peanut in infants 
with positive markers of sensitization reduced the risk of peanut 
allergy up to 80% compared with infants that avoided the allergen. 
Then a 12-month avoidance period did not reverted the clinical 
tolerance achieved [10]. However, there is no evidence to decide 
whether prevention strategies including allergen intervention should 
be performed in the general population, irrespective of the allergen-
containing food consumption of the population, environmental 
exposure to the allergen, an allergen-free diet followed by mothers 
during pregnancy and lactation, etc. [11].
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Food allergy, along with other allergic diseases, has increased in 
prevalence in westernized countries in the last decade and results 
from the interaction of different factors such as age, genetic load, 
immunogenicity and conformational features of food proteins 
and composition of the microbiota, among others. Food allergies 
are immune-mediated adverse reactions to food proteins and they 
can be IgE-mediated (causing immediate symptoms and potential 
anaphylaxis), non-IgE mediated (causing delayed reactions), or a 
combination of both. Food allergies involve different target organs 
and hence clinical presentation is variable and heterogeneous. It is 
not a unique clinical entity.
Emerging studies show that a loss of oral tolerance or a failure 
to induce tolerance is implicated in its immune-pathogenesis. The 
critical role of regulatory T cells (Treg) in tolerance development 
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The mechanisms by which immunotherapy works in allergic 
rhinitis, asthma, allergic conjunctivitis and bee venom allergy 
are mostly based on complex mechanisms that induce allergen 
tolerance. By contrast, the mechanisms by which allergen-specific 
immunotherapy works in food allergy are poorly understood. It is 
widely known that the main mechanism that is induced during the 
controlled mucosal administration of the offending allergen is the 
induction of T cell tolerance. The term tolerance is defined as a lack 
of adaptive immunity response to harmless antigens, which does not 
mean lack of response, but induction of several regulatory circuits 
that control both innate and adaptive immune responses involved in 
inflammation. Regulatory T cells have attracted the attention since its 
resurgence decades after they were discovered in the 70’s [12], and 
were described as key cells in immune-modulation. Nevertheless, 
special subsets of dendritic cells, NK cells or innate lymphocytes, 
macrophages and B cells have been involved in the regulation of the 
allergic reaction. While IgG4 and/or IgA are responsible to block 
the access of the allergen to antigen presenting cells and sensitized 
mast cells/basophils/eosinophils, induced-specific Treg can modulate 
the threshold for mast cell/basophil activation, control memory T 
cells, differentiation and tissue homing of Th2 cells, suppression of 
IgE-producing plasma cells, and induction of regulatory B cells and 
regulatory dendritic cells [13].
Despite the significant progress made in identifying the underlying 
mechanisms that govern the subcutaneous immunotherapy (SCIT), 
the high rate of systemic reactions elicited during treatment of food 
allergic patients, made these protocols inadequate for these patients 
[14]. More recently, and based on the better knowledge of human 
intestinal immune system and tolerance induction against oral 
antigens, oral immunotherapy (OIT), sublingual immunotherapy 
(SLIT) and epicutaneous immunotherapy (EPIT) have been evaluated 
as novel therapeutic options for food allergy. The mechanisms by 
which these immunotherapies might work are less studied [15]. 
These therapies rely on the administration (ingestion for OIT, held 
under the tongue for SLIT and skin contact for EPIT) of small and 
increasing amounts of the allergen, followed with a maintenance 
dose for a currently undefined duration of time. Although promising 
results were achieved, adverse reactions have been the main 
drawback in clinical trials, which in many cases affects therapeutic 
adherence. Therefore, and notwithstanding the great advances made 
in understanding the basis for these therapies, efforts are needed for 
optimization safety and efficacy.
Currently, clinical trials for several candidate immunotherapy 
protocols for food allergy are in various phases, with significant 
successes noted in clinical outcomes and modulation of immune 
mechanisms [6]. Two possible states of unresponsiveness against the 
allergen can be accomplished during the different investigational 
approaches: desensitization or tolerance. The former refers to the 
lack of reaction to allergen during the regular daily exposure to 
allergen on the maintenance dosing, which is achieved in most cases 
(patients regain sensitization after the treatment). True tolerance is 
the permanent absence of symptoms after the therapeutic exposure 
to allergen. This is the decisive goal of immunotherapy: patients can 
resume symptom-free consumption of the previously allergenic food. 
Although desensitization is the desired outcome of the interventional 
strategy, tolerance is the state considered for the onset of disease 
resolution. It is not clear which cells and mechanisms govern both 
states, and, mainly, which are the factors that affect the outcome of 
the treatment. Currently, oral food challenge (OFC) is performed at 
the end of the protocol to evaluate the dose of allergen that provokes 
symptoms. However, biomarkers that monitor the progress of the 
treatment (peripheral cells, peripheral cellular responses, antibodies, 
cytokines, etc), not currently available, will help to predict the 
effectiveness of immunotherapy.
Although there are inconsistencies between studies, in terms of 
protocol definitions and OFC implementation, a continuous success 
in amelioration of symptoms, increase of the threshold to have 
a positive OFC and reduction of adverse reaction with increased 
adherence has been observed for more than a decade in clinical trials. 
The protocolization of a controlled administration of the allergen 
and better-designed clinical trials rendered apparently more effective 
regulatory mechanisms, as shown by 20- to 100-fold or even greater 
improvement of OFC performance from baseline after treatment 
[16-18], with a decrease in SPT size and reduction of adverse effects 
up to 10% of patients involved in the trial [16]. Nevertheless, several 
trials have demonstrated that tolerance induction is transient and 
symptoms relapse in weeks or months if exposure to the food is 
resumed [19-21]. The IMPACT clinical trial (The Immune Tolerance 
Network), a randomized 3-year OIT (134 weeks of OIT followed by 
26 weeks of allergen avoidance), was launched in 2013 to investigate 
long-term tolerance in 144 peanut-allergic children.
Unfortunately the term tolerance has a wide meaning and 
probably several and complex mechanisms that involve soluble 
factors (IL-10, TGF-β, IL-35, IL-25, IL-27, etc), cell-cell contacts 
(CTLA-4, PD-1, etc), and different cell subsets of innate (innate 
lymphocytes, dendritic cells and macrophages) and adaptive 
immunity (B and T cells) are implicated in the control of the Th2-
mediated allergic immune response and outgrown of allergy. This 
emphasizes the need for further studies to identify which are the 
most powerful mechanisms that can address a long-term protection. 
In this sense, two approaches can be proposed to achieve tolerance: 
immunomodulation through the induction of the contra-regulatory 
Th1 cells, and tolerance through the Treg-mediated regulatory 
mechanisms that control innate and adaptive immune response.
In this regard, mouse models that resemble allergic diseases in 
human provide an essential tool for studying the pathogenesis of these 
inflammatory disorders, and the development of novel therapies. In 
order to elicit an allergic sensitization in mice, species that does not 
spontaneously develop allergy due to its genetic background, a pro-
Th2 mucosal adjuvant should be used. Cholera toxin or Staphylococcus 
enterotoxin B are the most widely employed adjuvants to breakdown 
oral tolerance to the co-administered antigens. Several protocols of 
oral sensitization to food antigens have proved to induce secretion of 
antigen-specific IgE and a cellular immune response skewed to Th2 
profile that promotes the induction of immediate hypersensitivity 
reactions upon challenge with the allergen [22,23]. Considering this 
parallel with human food allergy, animal models of experimental 
allergy that lead to mucosal allergic sensitization have shown to be 
useful biological tools to optimize and validate existing treatments as 
well as to develop novel specific and safer therapies [24].
Mouse models were used to optimize OIT in terms of reducing 
adverse side effects. The use of different anti-IgE monoclonal 
antibodies has shown promise to block soluble IgE or membrane-
bound IgE (BCR on memory IgE-switched B cells). In humans, a 
large body of research demonstrated that the anti-IgE therapy with 
Omalizumab, a humanized monoclonal antibody that blocks the 
binding of IgE to the high-affinity receptor, has shown to be effective 
at reducing circulating IgE antibodies and IgE-receptors (FcεRI) 
on sensitized cells (mainly mast cells and basophils), alongside the 
induction of histamine-specific inhibitory receptors (H4) in mast cells, 
[25] in asthma and rhinitis, while the new generation of humanized 
antibodies with 400-fold higher affinity for the inhibitory receptor 
FcγRIIb on B cells suppresses the generation of IgE-producing plasma 
cells [26]. In food allergy, although Omalizumab showed promising 
results in combination with oral immunotherapy for peanut allergy 
[27], the long-term efficacy is controversial. In addition, a humanized 
mouse model of asthma was successfully treated with an anti-IgE 
monoclonal antibody that reduced the frequency of IgE-switched 
B cells and the level of soluble IgE. Since it was demonstrated that 
apoptosis of IgE-memory B cells was induced it could be proposed 
as a long-lasting treatment for IgE-mediated diseases [28]. Another 
therapeutic strategy assessed in mice has been the use of peptides 
containing T epitopes or a single B epitope through the oral route. 
This approach has showed to be safe and effective in animal models of 
asthma to mites [29] and food allergy to egg [30].
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Sublingual immunotherapy also shows promising since very low 
doses of the allergen are administered under the tongue to activate 
the local immune system [31]. Although most of the SLIT studies 
have focused on inhalant allergies, emerging clinical trials with 
SLIT have shown hopeful results at inducing desensitization in food 
allergy [32]. However, only few studies have been done in hazelnut, 
peanut, kiwi, peach and cow’s milk allergy [33-38], and yet SLIT 
is not recommended for treatment of food allergy [5]. Despite the 
debatable efficacy of SLIT, lower frequencies of adverse reactions 
have been reported in SLIT compared to OIT [39]. Additionally, 
the end SLIT dose used in clinical trials is much lower than OIT 
dose. Considering that the induction of Treg is the key mechanism 
underlying desensitization and tolerance, it has been reported that 
the current protocols of SLIT have a lower efficiency to induce Treg 
in the mouth mucosa compared with OIT. At present, neither OIT 
nor SLIT provides optimal safety and efficacy for treatment of food 
allergy. Literature shows scarce reports exploring SLIT in mouse 
models of rhinitis and asthma. Pre-clinical studies in animals may 
provide useful and novel information regarding the uptake of allergen 
by the Langerhans cells of the oral cavity and how Tregs are induced 
in the sublingual mucosa or in the regional lymph nodes [40]. The 
use of nanoparticles composed of carbohydrates may enhance safety 
of SLIT through protecting and directing allergen towards antigen 
presenting cells [31,41]. Therefore, it is a tempting field to speculate 
on novel SLIT protocols for therapeutic induction of mucosal 
tolerance in food allergy.
Finally, epicutaneous immunotherapy or EPIT, the most recent 
mucosal therapy, delivers the antigen on the skin surface. Although 
limited studies are published in food allergic patients, pre-clinical 
[42,43] and clinical trials using an allergen-embedded patch (milk 
and peanut) showed and acceptable safety profile, with positive 
clinical effects and mostly local adverse reactions ([44] and VIPES 
Study at https://clinicaltrials.gov/ct2/show/record/NCT01955109]). 
It has been shown that different skin dendritic cell subsets internalize 
allergens and traffic to draining lymph nodes to generate specific 
Tregs that control the systemic allergic immune response in mice 
[43].
In conclusion, immunotherapy appears to be a promising option 
for a disease-modifying therapy for IgE-mediated food allergy. 
Since anaphylaxis is a major drawback, and protocols show a lack of 
consistency, none of the current therapies are ready for wide-spread 
clinical use. In this scenario animal models hold great potential as 
powerful biological tools to assess new therapeutic strategies and for 
pre-clinical studies, to provide more safety and efficacy to current 
immunotherapies. Long-term and sustained tolerance should then be 
explored in clinical trials, based on developments made on molecular 
mechanisms of immune regulation that promotes allergen-tolerance.
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